Preclinical studies have long suggested that the response to anti-PD1/PDL1 therapy is contingent on an intact gut microbiome, and this is supported by recent research in melanoma, NSCLC and colorectal cancer patients (89, 90). The gene discussed is PDCD1; the disease is melanoma.